- Pardes Biosciences Inc (NASDAQ:PRDS) reported topline results from its Phase 2 clinical trial evaluating pomotrelvir (previously PBI-0451) for mild-to-moderate COVID-19 in vaccinated adults without risk factors for developing severe disease.
- Pomotrelvir did not meet the primary endpoint measured by the proportion of participants below the detection limit for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir versus placebo.
- 70% reached undetectable levels in the pomotrelvir-treated group versus 63% in the placebo group (p=0.57).
- Otherwise, healthy, vaccinated adults without risk factors for progression to severe disease experienced rapid clearance of the SARS-CoV-2 virus and evidence of rapid alleviation of targeted and key COVID-19 symptoms independent of treatment arm.
- The company will suspend further development of pomotrelvir and explore a range of strategic alternatives.
- As of March 31, 2023, the company’s preliminary cash, cash equivalents, and short-term investments totaled approximately $172.4 million, sufficient to fund operations for the next twelve months.
- Price Action: PRDS shares are up 6.82% at $1.41 on the last check Monday.
DZS Receives Favorable Nasdaq Listing Decision; Granted The Request Of DZS Inc. For Continued Listing On The Nasdaq Stock Market, Subject To The Co’s Compliance With Nasdaq’s Filing Requirement By August 5, 2024, Among Other Conditions
DZS (NASDAQ:DZSI), a global leader of broadband networking and AI-driven cloud software solutions, today announced that by decision dated April 23, 2024, the Nasdaq Hearings Panel (the "Panel") granted the request of DZS